Correspondence 0001104659-26-028073 from Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
Date: March 16, 2026 · CIK: 0001781983 · Accession: 0001104659-26-028073
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293609
Referenced dates: February 24, 2026
Letter
VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell File No. 333-293609
Re: Aprea Therapeutics, Inc. (the "Company") Registration Statement on Form S-3 Filed February 20, 2026
Dear Mr. Campbell:
This letter is submitted on behalf of the Company in response to the Staff's comment letter dated February 24, 2026 (the "Comment Letter") relating to the above-referenced Registration Statement on Form S-3 (the "Registration Statement").
Staff Comment 1. We note that you filed this registration statement more than 45 days after the end of your fiscal year. As such, you do not appear to meet the age of financial statement requirements of Rule 8-08(b) of Regulation S-X. Please revise to include audited financial statements for the fiscal year ended December 31, 2025.
Company Response. The Company respectfully advises the Staff that the Company has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 16, 2026. As a result, the audited financial statements for the fiscal year ended December 31, 2025, are now on file with the Commission and incorporated by reference into the Registration Statement in accordance with the incorporation by reference provisions of the Registration Statement.
The Company respectfully believes that the filing of the Form 10-K addresses the Staff's comment. The Company acknowledges the Staff may have further questions and will respond promptly to any additional comments.
Please do not hesitate to contact the undersigned at 206-839-4831with any questions.
Sincerely,
Patrick O'Malley, Esq.
Partner
DLA Piper LLP US
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Aprea Therapeutics, Inc. (the "Company") Registration Statement on Form S-3 Filed February 20, 2026 File No. 333-293609 Dear Mr. Campbell: This letter is submitted on behalf of the Company in response to the Staff's comment letter dated February 24, 2026 (the "Comment Letter") relating to the above-referenced Registration Statement on Form S-3 (the "Registration Statement"). Staff Comment 1. We note that you filed this registration statement more than 45 days after the end of your fiscal year. As such, you do not appear to meet the age of financial statement requirements of Rule 8-08(b) of Regulation S-X. Please revise to include audited financial statements for the fiscal year ended December 31, 2025. Company Response. The Company respectfully advises the Staff that the Company has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 16, 2026. As a result, the audited financial statements for the fiscal year ended December 31, 2025, are now on file with the Commission and incorporated by reference into the Registration Statement in accordance with the incorporation by reference provisions of the Registration Statement. The Company respectfully believes that the filing of the Form 10-K addresses the Staff's comment. The Company acknowledges the Staff may have further questions and will respond promptly to any additional comments. Please do not hesitate to contact the undersigned at 206-839-4831with any questions. Sincerely, Patrick O'Malley, Esq. Partner DLA Piper LLP US cc: Oren Gilad cc: John Hamill